Trading Cockpit

· checking…
Loading…
← CockpitCompetitor Analysis › 6696.TWO Lin BioScience, Inc.Open in the cockpit ↗

Lin BioScience, Inc.6696.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Taiwanese clinical-stage biotech developing drugs for eye disease, cancer and metabolic disorders.

≈ A small-cap clinical-stage biotechMomentum leader 100
Competitor Analysis ▸ ChartsOpen in the cockpit
Mkt cap
$3.74B
US dollars, full cap
$/day
$39.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-18.2 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · TWDNT$939.00
1Dn/a
1W+17.5%
1M+36.5%
3M+140.5%
6M+128.8%
YTD+136.5%
1Y+492.4%
ATR %7.7%
52w lowhigh3.1% off high

What Lin BioScience does

Taiwanese clinical-stage biotech developing drugs for eye disease, cancer and metabolic disorders.

Has no product sales and funds its trials by raising capital, so progress in late-stage studies decides its value; any future income would come from licensing deals or an approved drug. It is listed on Taiwan's over-the-counter market, the Taipei Exchange.

In one line: A small-cap clinical-stage biotech.

Products and services

  • LBS-008 (dry AMD/Stargardt)
  • LBS-007 (oncology)
  • LBS-002 (brain tumors)
  • LBS-009 (NASH/diabetes)

Where it sits in the supply chain

  • Biopharmaceuticals
  • Clinical-stage drug development
  • Ophthalmology + oncology pipeline

What could go right

  • Positive Phase 3 readout
  • FDA fast-track/orphan designations already granted

What could go wrong

  • Clinical trial failure risk
  • No approved product/revenue yet

Moat: none (IP / patents). Pre-revenue biotech; value rests on clinical trial outcomes and patent-protected pipeline.

Headquarters: Taipei, Taiwan · Founded: 2016 · Employees: 63

Named competitors

  • Adverum Biotechnologies private or unlisted
  • Taiwan Liposome Company private or unlisted
  • Apellis Pharmaceuticals private or unlisted
  • Astellas Pharma 4503.T
  • Annexon ANNX

Lin BioScience at a glance

Size Lin BioScience (6696.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $3.74B, the 108th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$939.00 on 6 Nov 2026.

Performance Over six months the shares gained 128.8%, against +2.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 21 in its peer set.

Capital Return on invested capital runs 18.2 points below its cost of capital (5.0% WACC).

Relative performance

10015020011 May 202611 Aug 20266 Nov 20266696.TWO 235Peer median 100
Six months, rebased to 100: Lin BioScience against the median of its 20 peers (local-currency closes).

Lin BioScience financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$0NT$0NT$0NT$0NT$0
Revenue growth—————
Gross profit-NT$31.5M-NT$23.8M-NT$20.2M-NT$17.9M-NT$11.2M
EBITDA-NT$3.94B-NT$2.83B-NT$1.44B-NT$1.08B-NT$434M
Net income-NT$1.61B-NT$1.36B-NT$744M-NT$687M-NT$314M
Free cash flow-NT$1.87B-NT$1.27B-NT$957M-NT$1.01B-NT$382M
Capital expenditureNT$26.9MNT$8.18MNT$7.35MNT$1.97MNT$22.4M
Total debtn/aNT$22.8MNT$34.0MNT$42.9MNT$46.5M

Quarterly statements and history in the cockpit →

Lin BioScience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%600161IOVAABCLTNGXELVNIRONRLAYVIRPDYN0020072228TLXDNLI6127ADPT0283006919603392BAVA6696.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Lin BioScience is the large dot.

Lin BioScience competitors and peer comparison

Head to head with its named competitors (6696.TWO vs 4503.T vs ANNX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Lin BioScience 6696.TWO$3.74B+129%n/an/an/an/a
Astellas Pharma 4503.T$28.2B+11%+19%23%1.9×-11.0%
Annexon ANNX$796M-26%n/an/an/an/a

How Lin BioScience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lin BioScience against its 20 peers (data as of 6 Nov 2026)
Measure6696.TWOPeer medianRank in peer set
1-month return+36.5%+0.4%highest of 21
6-month return+128.8%+2.5%2nd highest of 21
Distance from 52-week high-3.1%-26.8%highest of 21
ROIC minus cost of capital-18.2 pp-12.0 pp6th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lin BioScience 6696.TWOTaiwan$3.74B+129%n/an/an/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.76B-11%-13%21%4.8×3.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.64B+64%+35%-91%10.4×n/an/a
AbCellera Biologics ABCLUnited States$3.85B+149%+101%-340%51.7×n/an/a
Tango Therapeutics TNGXUnited States$3.63B-7%+121%-253%49.1×n/an/a
Enliven Therapeutics ELVNUnited States$3.62B+21%n/an/an/an/an/a
Disc Medicine IRONUnited States$3.50B+16%n/an/an/an/an/a
Relay Therapeutics RLAYUnited States$4.08B+46%+24%-2,999%308.8×n/an/a
Virbac VIRP.PAFrance$3.38B+5%+4%15%2.1×6.2%+9.4%
Dyne Therapeutics DYNUnited States$3.37B+3%n/an/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.37B-15%-11%17%5.6×16.7%-1.8%
XtalPi 2228.HKHong Kong$3.35B-34%+4%-127%26.3×n/an/a
Telix Pharmaceuticals TLX.AXAustralia$3.22B-6%+27%-1%3.9×n/an/a
Denali Therapeutics DNLIUnited States$3.22B+2%n/a-2,488%128.0×n/an/a
JOINN Laboratories (China) 6127.HKHong Kong$4.43B+9%+17%-4%15.1×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.47B+103%+50%-12%14.7×n/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.51B-13%-18%-1%2.8×32.2%+7.1%
HLB 028300.KSSouth Korea$3.06B-49%+29%-96%45.9×n/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.01B-37%-54%-6,983%6,237.3×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.72B-37%+8%-35%14.5×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.93B+27%-3%16%2.8×-2.0%+27.4%

Questions

Who are Lin BioScience's main competitors?
Named competitors: Adverum Biotechnologies (private or unlisted), Taiwan Liposome Company (private or unlisted), Apellis Pharmaceuticals (private or unlisted), Astellas Pharma (4503.T), Annexon (ANNX). The cockpit's measured peer set (industry) also includes Beijing Tiantan Biological Products (600161.SS), Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL), Tango Therapeutics (TNGX), Enliven Therapeutics (ELVN), Disc Medicine (IRON).
How has Lin BioScience stock performed?
Over six months to 6 Nov 2026 the shares returned +128.8% against +2.5% for the median peer; over one year +492.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.